RetinalGenix (RTGN) S-1 21 Jan 22 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2021
Cover [Abstract]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	RETINALGENIX TECHNOLOGIES INC.
Entity Central Index Key	0001836295
Entity Tax Identification Number	82-3936890
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1450 North McDowell Boulevard
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Petaluma
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94954
City Area Code	415
Local Phone Number	578-9583
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash	$ 36,578	$ 2,219	$ 54,381
Due from Sanovas		15,069
Deferred Offering Costs		43,787
Total Current Assets	36,578	61,075	54,381
TOTAL ASSETS	36,578	61,075	54,381
Current Liabilities
Shareholder’s Loans	73,000		25,000
Accounts Payable	210,873	141,431	5,217
Due to Sanovas	164,233
Accrued Interest	1,180
Total Liabilities	449,286	141,431	30,217
Stockholders’ Deficit:
Preferred stock, Value	300	300	300
Common stock, Value	4,194	4,067	3,892
Additional paid in capital	4,277,676	2,840,599	867,301
Preferred stock subscription receivable	(300)	(300)	(300)
Accumulated deficit	(4,694,578)	(2,925,022)	(847,029)
Total stockholders’ deficit	(412,708)	(80,356)	24,164
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 36,578	$ 61,075	$ 54,381

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	40,000,000	40,000,000	40,000,000
Preferred stock, shares issued	3,000,000	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000	3,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	80,000,000	80,000,000	80,000,000
Common stock, shares issued	41,933,654	40,678,323	38,915,056
Common stock, shares outstanding	41,933,654	40,678,323	38,915,056

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue
Costs and expenses
Administrative	293,893	413,151	949,945	1,077,450	1,426,230	527,259
Research and Development	200,899	98,896	565,564	222,193	431,557	250,780
Stock-based compensation	55,051	55,051	252,867	165,153	220,206	27,776
Total Operating Expenses	549,843	567,098	1,768,376	1,464,796	2,077,993	805,815
(Loss) from operations					(2,077,993)	(805,815)
Interest expense	1,180		1,180
Net Loss	$ (551,023)	$ (567,098)	$ (1,769,556)	$ (1,464,796)	$ (2,077,993)	$ (805,815)
Net Loss per share - basic and diluted	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.04)	$ (0.05)	$ (0.02)
Weighted average number of common shares outstanding during the period- basic and diluted	41,825,154	39,996,806	41,303,545	39,507,084	39,696,697	35,471,382

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Preferred Stock [Member]Series F Preferred Stock [Member]	Subscription Receivable Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2018	$ 2,700	$ 300	$ (300)	$ 284	$ (2,984)
Beginning balance, shares at Dec. 31, 2018	27,000,000	3,000,000
Stock based compensation				27,776		27,776
Exercise of stock options	$ 250					$ 250
Exercise of stock options, shares	2,500,000					2,500,000
Exercise of warrants	$ 896					$ 896
Exercise of warrants, shares	8,964,000
Capital contribution by Sanovas (Note C)				350,000		350,000
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC	$ 27			266,030		266,057
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares	266,056
Stock purchased by investors	$ 19			184,981		185,000
Stock purchased by investors, shares	185,000
Deemed dividend				38,230	(38,230)
Net loss					(805,815)	(805,815)
Ending balance, value at Dec. 31, 2019	$ 3,892	$ 300	(300)	867,301	(847,029)	24,164
Ending balance, shares at Dec. 31, 2019	38,915,056	3,000,000
Stock based compensation				55,051		55,051
Stock purchased by investors	$ 38			376,962		377,000
Stock purchased by investors, shares	377,000
Net loss					(466,837)	(466,837)
Ending balance, value at Mar. 31, 2020	$ 3,930			1,299,314	(1,313,866)	(10,622)
Ending balance, shares at Mar. 31, 2020	39,292,056
Beginning balance, value at Dec. 31, 2019	$ 3,892	$ 300	(300)	867,301	(847,029)	24,164
Beginning balance, shares at Dec. 31, 2019	38,915,056	3,000,000
Net loss						(1,464,796)
Ending balance, value at Sep. 30, 2020	$ 4,034			2,441,766	(2,311,825)	133,975
Ending balance, shares at Sep. 30, 2020	40,324,510
Beginning balance, value at Dec. 31, 2019	$ 3,892	$ 300	(300)	867,301	(847,029)	24,164
Beginning balance, shares at Dec. 31, 2019	38,915,056	3,000,000
Stock based compensation				220,206		$ 220,206
Exercise of stock options, shares
Capital contribution by Sanovas (Note C)
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC	$ 35			358,091		358,126
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares	358,126
Stock purchased by investors	$ 140			1,395,001		1,395,141
Stock purchased by investors, shares	1,405,141
Net loss					(2,077,993)	(2,077,993)
Ending balance, value at Dec. 31, 2020	$ 4,067	$ 300	(300)	2,840,599	(2,925,022)	(80,356)
Ending balance, shares at Dec. 31, 2020	40,678,323	3,000,000
Beginning balance, value at Mar. 31, 2020	$ 3,930			1,299,314	(1,313,866)	(10,622)
Beginning balance, shares at Mar. 31, 2020	39,292,056
Stock based compensation				55,051		55,051
Stock purchased by investors	$ 26			257,644		257,670
Stock purchased by investors, shares	257,670
Net loss					(430,861)	(430,861)
Ending balance, value at Jun. 30, 2020	$ 3,956			1,612,009	(1,744,727)	(128,762)
Ending balance, shares at Jun. 30, 2020	39,549,726
Stock based compensation				55,051		55,051
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC	$ 36			358,090		358,126
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares	358,126
Stock purchased by investors	$ 42			416,616		416,658
Stock purchased by investors, shares	416,658
Net loss					(567,098)	(567,098)
Ending balance, value at Sep. 30, 2020	$ 4,034			2,441,766	(2,311,825)	133,975
Ending balance, shares at Sep. 30, 2020	40,324,510
Beginning balance, value at Dec. 31, 2020	$ 4,067	$ 300	(300)	2,840,599	(2,925,022)	(80,356)
Beginning balance, shares at Dec. 31, 2020	40,678,323	3,000,000
Stock based compensation				111,487		111,487
Stock purchased by investors	$ 40			398,057		398,097
Stock purchased by investors, shares	398,097
Net loss					(683,681)	(683,681)
Ending balance, value at Mar. 31, 2021	$ 4,107			3,350,143	(3,608,703)	(254,453)
Ending balance, shares at Mar. 31, 2021	41,076,420
Beginning balance, value at Dec. 31, 2020	$ 4,067	$ 300	$ (300)	2,840,599	(2,925,022)	$ (80,356)
Beginning balance, shares at Dec. 31, 2020	40,678,323	3,000,000
Exercise of stock options, shares
Net loss						$ (1,769,556)
Ending balance, value at Sep. 30, 2021	$ 4,194			4,277,676	(4,694,578)	(412,708)
Ending balance, shares at Sep. 30, 2021	41,933,654
Beginning balance, value at Mar. 31, 2021	$ 4,107			3,350,143	(3,608,703)	(254,453)
Beginning balance, shares at Mar. 31, 2021	41,076,420
Stock based compensation				86,329		86,329
Exercise of warrants	$ 1			13,499		13,500
Exercise of warrants, shares	13,500
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC	$ 39			390,319		390,358
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares	390,358
Stock purchased by investors	$ 27			263,349		263,376
Stock purchased by investors, shares	263,376
Net loss					(534,852)	(534,852)
Ending balance, value at Jun. 30, 2021	$ 4,174			4,103,639	(4,143,555)	(35,742)
Ending balance, shares at Jun. 30, 2021	41,743,654
Stock based compensation				55,051		55,051
Stock purchased by investors	$ 20			189,980		190,000
Stock purchased by investors, shares	190,000
Costs of stock sales				(70,994)		(70,994)
Net loss					(551,023)	(551,023)
Ending balance, value at Sep. 30, 2021	$ 4,194			$ 4,277,676	$ (4,694,578)	$ (412,708)
Ending balance, shares at Sep. 30, 2021	41,933,654

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities
Net Loss	$ (1,769,556)	$ (1,464,796)	$ (2,077,993)	$ (805,815)
Stock based compensation expense	252,867	165,153	220,206	27,776
Costs and expenses paid on behalf of Company by Sanovas, net	569,657	236,739	358,126	616,057
Changes in operating assets and liabilities:
Increase in current assets			(58,856)
Increase in accounts payable	69,446	12,282	136,214	5,217
Increase in accrued interest	1,180
Total Adjustments	893,150	414,174
Net cash used in operating activities	(876,406)	(1,050,622)	(1,422,303)	(156,765)
Cash Flows From Financing Activities
Change in stockholders refund payable, net		(25,000)	(25,000)	25,000
Proceeds from common stock sold, net of costs	824,265	1,051,331	1,395,141	185,000
Proceeds from shareholder loans	73,000
Proceeds from exercise of warrants	13,500			896
Proceeds from exercise of options		250		250
Net cash provided by financing activities	910,765	1,026,331	1,370,141	211,146
Net increase (decrease) in cash	34,359	(24,291)	(52,162)	54,381
Cash at beginning of period	2,219	54,381	54,381
Cash at end of period	36,578	30,090	2,219	54,381
Supplemental information:
Retirement of due to Sanovas to capital through the issuance of common stock to Sanovas Ophthalmology LLC (Note C)	390,358	358,126	358,126	266,057
Capital contribution by Sanovas				$ 350,000

HISTORY, BUSINESS PURPOSE, LIQU

HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN	NOTE A – HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN RetinalGenix Technologies Inc. (the “Company”), a Delaware corporation, was formed in November 2017 by Sanovas Ophthalmology, LLC (“Sanovas Ophthalmology”), a majority owned subsidiary of Sanovas Inc. (“Sanovas”), a privately held research and development incubator. At September 30, 2021 and December 31, 2020, Sanovas Ophthalmology owns a majority of the outstanding stock of the Company. During the nine months ended September 30, 2021 and 2020, substantially all of the operations of the Company were conducted by Sanovas, who invoices the Company for reimbursement for services and costs performed on behalf of the Company. The Company was formed to develop technologies to diagnose and treat optical disorders. The Company sublicensed certain technology initially developed by Sanovas from Sanovas Ophthalmology – See Note C. Since 2018, the Company has been developing its screening device and home monitoring and physician alert system. In October 2021, the Company filed a registration on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission pursuant to which it registered for resale shares of common stock, including shares of common stock issuable upon exercise of outstanding options and warrants. The Company did not raise any cash from the resale of the securities offered by the Registration Statement, and accordingly, the previously deferred offering costs were applied against the proceeds of the shares of common stock sold from 2019 through September 30, 2021 pursuant to the Company’s previous private offering of securities. On October 8, 2019, the Company entered into an option exchange agreement (the “Option Exchange Agreement”) with Diopsys, Inc. (“Diopsys”) pursuant to which the Company shall issue Diopsys an option to purchase up to 10% 10% Liquidity and Going Concern The Company expects that operating losses and negative cash flows from operations will occur for at least the next several years, and the Company will need to access additional funds to achieve its strategic goals with respect to the sublicensed technology. Sanovas has paid most of the Company’s operating expenses through September 2021. The Company commenced private offerings of shares of its common stock raising gross proceeds of approximately $ 1,395,000 in the year ended December 31, 2020, and $ 851,000 for the nine months ended September 30, 2021 - See Note D. The Company also issued shares of its common stock to offset amounts due to Sanovas for payment of bills on behalf of the Company of $ 390,358 in June 2021 and $ 358,126 in July RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE A – HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN - continued The Company will seek to raise substantial funds through the sale of common stock, through debt financing and/or through establishing strategic collaboration agreements. In February 2020, the Company entered into an agreement with an investment banker to support fundraising or strategic transactions. This agreement was terminated in March 2021. In February 2021, the Company entered into a new agreement with an investment banker to raise funds for the Company. The Company does not know whether additional financing will be available when needed, whether it will be available on favorable terms, or if it will be available at all. As of the date of this report, the Company does not have adequate resources to fund its operations through September 2022 without considering any potential future milestone payments that it may receive under any new collaborations that it may enter into in the future or any future capital raising transactions. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.	NOTE A – HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN RetinalGenix Technologies Inc. (the “Company”), a Delaware corporation, was formed in November 2017 by Sanovas Ophthalmology LLC, a majority owned subsidiary of Sanovas Inc. (“Sanovas”), a privately held research and development incubator. At December 31, 2020 and 2019, Sanovas Ophthalmology LLC (“Sanovas Ophthalmology”) owns a majority of the outstanding stock of the Company. Through December 31, 2018, the Company was largely inactive. During the years ended December 31, 2020 and 2019, substantially all of the operations of the Company were conducted by Sanovas, who invoices the Company for reimbursement for services and costs performed on behalf of the Company. RetinalGenix Technologies Inc. was formed to develop technologies to diagnose and treat optical disorders. The Company may license technology initially developed by Sanovas, depending on negotiation and execution of a technology license or it may develop/license technologies from other parties. Since 2018, the Company has been developing its screening device and home monitoring and physician alert system. On October 8, 2019, the Company entered into an option exchange agreement (the “Option Exchange Agreement”) with Diopsys, Inc. (“Diopsys”) pursuant to which the Company shall issue Diopsys an option to purchase up to 10 10 Liquidity and Going Concern The Company expects that operating losses and negative cash flows from operations will occur for at least the next several years, and the Company will need to access additional funds to achieve its strategic goals with respect to the licensed technology. Sanovas has paid most of the Company’s operating expenses through December 2020. The Company commenced a private offering of shares of its common stock in November 2019 raising approximately $ 185,000 1,395,000 350,000 358,000 266,000 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE A – HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN - continued The Company will seek to raise substantial funds through the sale of common stock, through debt financing or through establishing strategic collaboration agreements. In February 2020, the Company entered into an agreement with an investment banker to support fundraising or strategic transactions. This agreement was terminated in March 2021. In February 2021, the Company entered into a new agreement with an investment banker to raise funding for the Company. The Company does not know whether additional financing will be available when needed, whether it will be available on favorable terms, or if it will be available at all. As of the date of this report, the Company does not have adequate resources to fund its operations through May 2022 without considering any potential future milestone payments that it may receive under any new collaborations that it may enter into in the future or any future capital raising transactions. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE B - SIGNIFICANT ACCOUNTING POLICIES A summary of significant accounting policies consistently applied in the preparation of the accompanying financial statements is as follows: 1. Basis of Presentation The Company’s financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). 2. Cash Equivalents For purpose of the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents. 3. Deferred Offering Costs Deferred offering costs are expenses directly related to an expected financing. These costs consisted of legal fees that the Company capitalized which will be offset against the proceeds upon completion of such future financing. During the quarter ended September 30, 2021, all such costs were charged against additional paid in capital for the funds raised during 2021. 4. Use of Estimates In preparing the Company’s financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE B - SIGNIFICANT ACCOUNTING POLICIES - continued 5. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740-10 Income Taxes no no 6. Income (Loss) Per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earnings Per Share Potentially dilutive securities not included in the computation of loss per share for the nine months ended September 30, 2021 included 3,000,000 1,820,000 199,000 3,000,000 1,800,000 62,500 4,193,000 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE B - SIGNIFICANT ACCOUNTING POLICIES - continued 7. Stock-based compensation The Company recognizes expense for stock-based compensation in accordance with ASC Topic 718, Stock-Based Compensation 8. Research and Development costs Research and development costs are expensed as incurred. 9. Recent Accounting Pronouncements The following pronouncement may have an impact on the accounting policies of the Company: In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, Classification of Certain Cash Receipts and Cash Payments A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether the implementation of such proposed standards would be material to the financial statements of the Company.	NOTE B - SIGNIFICANT ACCOUNTING POLICIES A summary of significant accounting policies consistently applied in the preparation of the accompanying financial statements is as follows: 1. Basis of Presentation The Company’s financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). 2. Cash Equivalents For purpose of the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents. 3. Deferred Offering Costs Deferred offering costs are expenses directly related to the expected financing. These costs consisted of legal fees that the Company capitalized which will be offset against the proceeds upon completion of the financing. 4. Use of Estimates In preparing the Company’s financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE B - SIGNIFICANT ACCOUNTING POLICIES – continued 5. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740-10 Income Taxes no no 6. Income (Loss) Per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earnings Per Share Potentially dilutive securities not included in the computation of loss per share at December 31, 2020 and 2019 included 3,000,000 1,800,000 62,500 4,067,832 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE B - SIGNIFICANT ACCOUNTING POLICIES - continued 7. Stock-based Compensation The Company recognizes expense for stock-based compensation in accordance with ASC Topic 718, Stock-Based Compensation 8. Research and Development Costs Research and development costs are expensed as incurred. 9. Recent Accounting Pronouncements The following pronouncements may have an impact on the accounting policies of the Company: In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, Classification of Certain Cash Receipts and Cash Payments A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether the implementation of such proposed standards would be material to the financial statements of the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE C - RELATED PARTY TRANSACTIONS The Company is related to Sanovas through common ownership and management. Commencing in 2019, Sanovas began paying invoices on behalf of the Company, and began allocating a portion of salaries and infrastructure costs to the Company and other entities where Sanovas was performing shared services. Included in such allocated costs is approximately $ 360,000 390,358 358,126 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE C - RELATED PARTY TRANSACTIONS, continued The following summarizes the transactions between the Company and Sanovas for the nine months ended September 30, 2021 and 2020: SCHEDULE OF RELATED PARTY TRANSACTIONS Nine Months Ended September 30, 2021 2020 Balance due from Sanovas – beginning of period $ (15,069 ) $ - Costs paid by Sanovas on the Company’s behalf 34,510 87,785 Costs of Sanovas allocated to the Company 750,639 1,248,154 Repayment of costs charged by Sanovas to the Company (215,489 ) (1,099,200 ) Subtotal 554,591 236,739 Retirement of due to Sanovas through the issuance of 390,358 358,126 (390,358 ) (358,126 ) Balance due to Sanovas at September 30, $ 164,233 $ (121,387 ) Sublicense On June 24, 2021, the Company entered into a sublicense agreement (“Sublicense Agreement”) with Sanovas Ophthalmology pursuant to which Sanovas Ophthalmology granted the Company an exclusive worldwide (“Territory”) license to certain intellectual property licensed to Sanovas Ophthalmology by Sanovas Intellectual Property LLC relating to certain technologies for eye and ocular visualization and monitoring (“Licensed IP”) for uses related to the screening, examination, diagnosis, prevention and/or treatment of any eye disease, medical condition or disorder, or any disease, medical condition or disorder affecting the eye. Pursuant to the Sublicense Agreement, commencing on the date of the first commercial sale of a Licensed Product (as defined in the Sublicense Agreement), in each country in the Territory and continuing on a country by country basis until the expiration or termination of the last Valid Claim (as defined in the Sublicense Agreement) of a licensed patent in such country (the “Royalty End Date”), the Company shall pay Sanovas Ophthalmology a royalty equal to a mid-single digit percentage of any Net Sales (as defined in the Sublicense Agreement) of any Licensed Product. The Sublicense Agreement shall continue until the Royalty End Date, unless earlier terminated pursuant to its terms. The Sublicense Agreement may be terminated by either party if the other party materially breaches the Sublicense Agreement in a manner that cannot be cured, or materially breaches the Sublicense Agreement in a manner that can be cured and such breach remains uncured for more than 30 days after the receipt by the breaching party of notice specifying the breach. Furthermore, the Company may terminate the Sublicense Agreement at any time upon 90 days written notice to Sanovas Ophthalmology. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020	NOTE C - RELATED PARTY TRANSACTIONS The Company is related to Sanovas through common ownership and management. Commencing in 2019, Sanovas began paying invoices on behalf of the Company, and began allocating a portion of salaries and infrastructure costs to the Company and other entities where Sanovas was performing shared services. Included in such allocated costs is approximately $ 780,000 266,056 358,126 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 The following summarizes the transactions between the Company and Sanovas for the years ended December 31, 2020 and 2019: SCHEDULE OF RELATED PARTY TRANSACTIONS Year ended December 31, 2020 2019 Balance due from Sanovas – beginning of period - - Costs paid by Sanovas on the Company’s behalf $ 127,967 $ 26,837 Costs of Sanovas allocated to the Company 1,301,246 692,420 Repayment of costs charged by Sanovas to the Company (1,086,156 ) (103,200 ) Subtotal 343,057 616,057 Capital Contribution by Sanovas (see Note F) - (350,000 ) Retirement of due to Sanovas through issuance of 358,126 266,056 (358,126 ) (266,057 ) Balance due from Sanovas $ 15,069 $ 0

COMMON AND PREFERRED STOCK

COMMON AND PREFERRED STOCK	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
COMMON AND PREFERRED STOCK	NOTE D - COMMON AND PREFERRED STOCK Pursuant to the Company’s Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), filed with the Delaware Secretary of State on January 8, 2018, the Company is authorized to issue 40,000,000 80,000,000 0.0001 3,000,000 Pursuant to the terms of an employment agreement dated January 1, 2012 (the “Effective Date”) by and between Sanovas and Lawrence Gerrans, the then President and Chief Executive Officer of Sanovas (the “Original Employment Agreement”), in consideration for Mr. Gerrans’ services, Mr. Gerrans was to receive, among other consideration, the following equity securities: (i) 441,177 7.5% 5,000 7.5% 5,000 27,000,000 3,000,000 In January 2020, a jury in the United States District Court for the Northern District of California found Mr. Gerrans guilty, in a criminal proceeding (the “Criminal Action”), on 12 felony counts of wire fraud, money laundering, perjury, contempt of court, witness tampering, and obstruction of justice in connection with his activities as an officer and director of Sanovas. Thereafter, in November 2020, Sanovas commenced an action in the Court of Chancery of the State of Delaware (the “Delaware Action”) against Halo and Mr. Gerrans seeking an order declaring that any rights that Halo and/or Mr. Gerrans may have with respect to any equity securities in Sanovas and each of its affiliated subsidiaries (including, but not limited to, the Company) are void or voidable and may be cancelled. The Delaware Action is currently still pending. The Company intends to take any and all actions required to assist Sanovas in obtaining a judgement against Halo and Mr. Gerrans in the Delaware Action declaring any shares issued to them void or voidable. See Note H. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 Common Stock During 2019, the Company commenced a private offering of its shares of common stock at a purchase price of $ 1.00 1,405,141 851,000 1,051,000 The common shareholders, voting as a separate class, are entitled to elect one member of the Board of Directors. Preferred Stock The rights and privileges of the Series F preferred stock are summarized as follows: Voting Privileges and Protective Features Each holder of outstanding shares of Series F preferred stock is entitled to cast the number of votes equal to the number of whole shares of common stock into which the Series F preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. The holders of record of a majority of outstanding Series F preferred stock shall be entitled to elect two of the members of the Board of Directors of the Company. The right to elect two directors shall terminate on the date upon which there are less than 25,000 shares of Series F preferred stock issued and outstanding. For so long as at least 25,000 Redemption The Series F preferred stock does not have redemption features. Dividends There is no Conversion Each share of Series F preferred stock is convertible, at the option of the holder, at any time and from time to time into shares of common stock at a conversion rate as is determined by dividing the Series F Original Issue Price by the Series F Conversion Price. “Series F Original Issue Price” initially means $ 0.01 0.01 All of the outstanding shares of Series F preferred stock will automatically convert into shares of the Company’s common stock upon the consummation of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in gross proceeds of at least $ 15,000,000 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020	NOTE D - COMMON AND PREFERRED STOCK Pursuant to the Company’s Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), filed with the Delaware Secretary of State on January 8, 2018, the Company is authorized to issue 40,000,000 80,000,000 0.0001 3,000,000 Pursuant to the terms of an employment agreement dated January 1, 2012 (the “Effective Date”) by and between Sanovas and Lawrence Gerrans, the then President and Chief Executive Officer of Sanovas (the “Original Employment Agreement”), in consideration for Mr. Gerrans’ services, Mr. Gerrans was to receive, among other consideration, the following equity securities: (i) 441,177 7.5 5,000 7.5 5,000 27,000,000 3,000,000 In January 2020, a jury in the United States District Court for the Northern District of California found Mr. Gerrans guilty, in a criminal proceeding (the “Criminal Action”), on 12 felony counts of wire fraud, money laundering, perjury, contempt of court, witness tampering, and obstruction of justice in connection with his activities as an officer and director of Sanovas. Thereafter, in November 2020, Sanovas commenced an action in the Court of Chancery of the State of Delaware (the “Delaware Action”) against Halo and Mr. Gerrans seeking an order declaring that any rights that Halo and/or Mr. Gerrans may have with respect to any equity securities in Sanovas and each of its affiliated subsidiaries (including, but not limited to, the Company) are void or voidable and may be cancelled. The Delaware Action is currently still pending. The Company intends to take any and all actions required to assist Sanovas in obtaining a judgement against Halo and Mr. Gerrans in the Delaware Action declaring any shares issued to them void or voidable. In the event that Sanovas is successful in obtaining a judgement against Halo and Mr. Gerrans in the Delaware Action declaring any shares issued to them void or voidable, the Company’s board of directors intends to take action to cancel any such shares. Alternatively, the Company’s board of directors continues to consider and explore any and all other actions or remedies which may be available to the Company to cancel such shares and/or declare such shares void or voidable. While no definitive action has been taken by the Company’s board of directors to date, the Company currently expects its board of directors to determine an appropriate course of action based upon the outcome of the Delaware Action. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE D - COMMON AND PREFERRED STOCK (CONTINUED) Common Stock During 2019, the Company commenced a private offering of its shares of common stock at a purchase price of $ 1.00 1,405,141 185,000 10,000 25,000 The common shareholders, voting as a separate class, are entitled to elect one member of the Board of Directors. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE D - COMMON AND PREFERRED STOCK (CONTINUED) Preferred Stock The rights and privileges of the Series F preferred stock are summarized as follows: Voting Privileges and Protective Features Each holder of outstanding shares of Series F preferred stock is entitled to cast the number of votes equal to the number of whole shares of common stock into which the Series F preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. The holders of record of a majority of outstanding Series F preferred stock shall be entitled to elect two of the members of the Board of Directors of the Company. The right to elect two directors shall terminate on the date upon which there are less than 25,000 shares of Series F preferred stock issued and outstanding. For so long as at least 25,000 Redemption The Series F preferred stock does not have redemption features. Dividends There is no Conversion Each share of Series F preferred stock is convertible, at the option of the holder, at any time and from time to time into shares of common stock at a conversion rate as is determined by dividing the Series F Original Issue Price by the Series F Conversion Price. “Series F Original Issue Price” initially means $ 0.01 0.01 All of the outstanding shares of Series F preferred stock will automatically convert into shares of the Company’s common stock upon the consummation of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in gross proceeds of at least $ 15,000,000 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019

STOCK PLAN

STOCK PLAN	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stock Plan
STOCK PLAN	NOTE E - STOCK PLAN The Company has reserved 10,000,000 In November 2019, the Company issued stock options to purchase up to 1,800,000 shares of common stock at an exercise price of $ 1.00 per share to members of the Company’s medical advisory board and consultants pursuant to the Plan. The options vest over a five year period and were unexercised at December 31, 2020 and September 30, 2021. The estimated aggregate fair value of the stock options was determined to be $ 1,101,028 using a Black Scholes model. In the nine months ended September 30, 2021, the Company issued stock options to purchase up to 20,000 shares of common stock at an exercise price of $ 1.00 per share to members of the Company’s medical advisory board and consultants pursuant to the Plan. The options vest immediately and were unexercised at September 30, 2021. The estimated aggregate fair value of the stock options was determined to be approximately $ 12,200 using a Black Scholes model. The Company recognized $ 252,867 and $ 165,153 of stock based compensation expense during the nine months ended September 30, 2021 and 2020, respectively, related to all stock options and warrants (see Note F) which is included in the accompanying statements of operations. As of September 30, 2021, there was approximately $ 688,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately 2.9 years. At September 30, 2021, there were 5,680,000 SCHEDULE OF STOCK OPTION ACTIVITY Options Issued Weighted- Options outstanding – December 31, 2019 1,800,000 $ 1.00 Granted - - Canceled - - Exercised - - Options outstanding – December 31, 2020 1,800,000 1.00 Granted 20,000 1.00 Canceled - - Exercised - - Options outstanding – September 30, 2021 1,820,000 $ 1.00 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE E - STOCK PLAN (continued) Additional information regarding the exercisable options and average remaining contractual life of the options outstanding as of September 30, 2021 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number Weighted Average Number December 31, Number September 30, $ 1.00 1,820,000 3.5 405,000 605,000 The fair value of each option grant was estimated on the date of grant to be $ 0.61 SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.42 % Expected life in years 5.0 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00 The risk-free interest rate assumption is determined using the yield currently available on U.S. Treasury zero-coupon issues with a remaining term commensurate with the expected term of the award. Management has estimated expected volatility based on similar comparable industry sector averages. Expected life of the option represents the period of time options are expected to be outstanding. The estimate for dividend yield is 0%	NOTE E - STOCK PLAN The Company has reserved 10,000,000 no In April 2019, the Company issued stock options to purchase up to 2,500,000 0.0001 250 In November 2019, the Company issued stock options to purchase up to 1,800,000 1.00 1,101,028 The Company recognized $ 220,206 27,776 1,074,000 3.8 At December 31, 2020, there are 5,700,000 SCHEDULE OF STOCK OPTION ACTIVITY Options Issued Weighted-Average Exercise Price Options outstanding December 31, 2018 - - Granted 4,300,000 $ 0.42 Canceled - - Exercised (2,500,000 ) $ 0.0001 Options outstanding – December 31, 2019 1,800,000 $ 1.00 Granted - - Canceled - - Exercised - - Options outstanding – December 31, 2020 1,800,000 $ 1.00 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE E - STOCK PLAN (continued) Additional information regarding the exercisable options and average remaining contractual life of the options outstanding as of December 31, 2020 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable at December 31, 2020 Number Exercisable at December 31, 2019 $ 1.00 1,800,000 4 405,000 45,000 The fair value of each option grant was estimated on the date of grant to be $ 0.61 SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.38 % Expected life in years 5.0 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00 The risk-free interest rate assumption is determined using the yield currently available on U.S. Treasury zero-coupon issues with a remaining term commensurate with the expected term of the award. Management has estimated expected volatility based on similar comparable industry sector averages. Expected life of the option represents the period of time options are expected to be outstanding. The estimate for dividend yield is 0

WARRANTS

WARRANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Warrants
WARRANTS	NOTE F - WARRANTS In 2021, the Company finalized the issuance of warrants to purchase 150,000 1.10 7 0.61 SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.42 % Expected life in years 3.5 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 The risk-free interest rate assumption is determined using the yield currently available on U.S. Treasury zero-coupon issues with a remaining term commensurate with the expected term of the award. Management has estimated expected volatility based on similar comparable industry sector averages. Expected life of the option represents the period of time options are expected to be outstanding. The estimate for dividend yield is 0% because the Company has not historically paid, and does not intend to pay a dividend on its common stock in the foreseeable future. The Company recognized stock-based compensation expense related to these warrants of approximately $ 75,500 in the nine months ended September 30, 2021. At September 30, 2021, there is no remaining compensation expense to be recognized. The following table summarizes warrant activity during 2021 and 2020: SCHEDULE OF WARRANTS ACTIVITY Warrants Issued Weighted- Warrants outstanding – December 31, 2019 62,500 $ 1.00 Granted - - Canceled - - Exercised - - Warrants outstanding – December 31, 2020 62,500 $ 1.00 Granted 150,000 $ 1.10 Canceled - - Exercised (13,500 ) $ 1.00 Warrants outstanding – September 30, 2021 199,000 $ 1.07 Additional information regarding the warrants outstanding as of September 30, 2021 is as follows: SCHEDULE OF WARRANTS OUTSTANDING Exercise Number Weighted Average Number $ 1.00 49,000 1.7 49,000 $ 1.10 150,000 6.2 150,000 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020	NOTE F - WARRANTS SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.42 % Expected life in years 3.5 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00 In March 2019, the warrant holders paid $ 929 9,288,000 0.0001 324,000 324,000 32 8,964,000 896 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 Sanovas Offering During 2019, Sanovas commenced a $ 5,000,000 350,000 three 62,500 1.00 38,230 The following table summarizes warrant activity during 2020 and 2019: SCHEDULE OF WARRANTS ACTIVITY Warrants Issued Weighted-Average Exercise Price Warrants outstanding - December 31, 2018 8,640,000 $ 0.0001 Granted 62,500 $ 1.00 Canceled - - Exercised (8,640,000 ) $ 0.0001 Warrants outstanding – December 31, 2019 62,500 $ 1.00 Granted - - Canceled - - Exercised - - Warrants outstanding – December 31, 2020 62,500 $ 1.00 Additional information regarding the exercisable warrants and average remaining contractual life of the warrants outstanding as of December 31, 2020 is as follows: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable $ 1.00 62,500 2.5 62,500 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019

INCOME TAXES

INCOME TAXES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE G – INCOME TAXES At December 31, 2020, the Company had net operating loss carryforwards (“NOL”) of approximately $ 2,058,000 1,283,000 775,000 2,058,000 The resulting net deferred tax assets of approximately $ 788,000 232,000 556,000 232,000 Due to the change in ownership provisions of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), the availability of the Company’s NOL carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the NOL carryforward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax asset with an offsetting reduction in the valuation allowance. The open years for tax examination are 2017 and thereafter.	NOTE G – INCOME TAXES At December 31, 2020, the Company had net operating loss carryforwards (“NOL”) of approximately $ 2,058,000 1,283,000 775,000 2,058,000 The resultant net deferred tax assets of approximately $ 788,000 232,000 556,000 232,000 Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s NOL carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the NOL carryforward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax asset with an offsetting reduction in the valuation allowance. The open years for tax examination are 2017 and thereafter.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE H - SUBSEQUENT EVENTS Subsequent events were reviewed through November 22, 2021, the date these financial statements were available for issuance. From October 2021 through November 19, 2021, the Company sold 170,000 1.00 On November 21,2021, the Company’s Board of Directors resolved to rescind the 3,000,000	NOTE H - SUBSEQUENT EVENTS Subsequent events were reviewed through June 24, 2021, the date these financial statements were available for issuance. From January 2021 through June 24, 2021, the Company sold 664,973 1.00 In 2021, the Company finalized the issuance of warrants to purchase 150,000 1.10 7 On June 24, 2021, the Company entered into a sublicense agreement (“Sublicense Agreement”) with Sanovas Ophthalmology pursuant to which Sanovas Ophthalmology granted the Company an exclusive worldwide (“Territory”) license to certain intellectual property licensed to Sanovas Ophthalmology by Sanovas Intellectual Property LLC relating to certain technologies for eye and ocular visualization and monitoring (“Licensed IP”) for uses related to the screening, examination, diagnosis, prevention and/or treatment of any eye disease, medical condition or disorder, or any disease, medical condition or disorder affecting the eye. Pursuant to the Sublicense Agreement, commencing on the date of the first commercial sale of a Licensed Product (as defined in the Sublicense Agreement), in each country in the Territory and continuing on a country by country basis until the expiration or termination of the last Valid Claim (as defined in the Sublicense Agreement) of a licensed patent in such country (the “Royalty End Date”), the Company shall pay Sanovas Ophthalmology a royalty equal to a mid-single digit percentage of any Net Sales (as defined in the Sublicense Agreement) of any Licensed Product. The Sublicense Agreement shall continue until the Royalty End Date, unless earlier terminated pursuant to its terms. The Sublicense Agreement may be terminated by either party if the other party materially breaches the Sublicense Agreement in a manner that cannot be cured, or materially breaches the Sublicense Agreement in a manner that can be cured, and such breach remains uncured for more than 30 days after the receipt by the breaching party of notice specifying the breach. Furthermore, the Company may terminate the Sublicense Agreement at any time upon 90 days written notice to Sanovas Ophthalmology.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The Company’s financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).	1. Basis of Presentation The Company’s financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Cash Equivalents	2. Cash Equivalents For purpose of the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents.	2. Cash Equivalents For purpose of the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents.
Deferred Offering Costs	3. Deferred Offering Costs Deferred offering costs are expenses directly related to an expected financing. These costs consisted of legal fees that the Company capitalized which will be offset against the proceeds upon completion of such future financing. During the quarter ended September 30, 2021, all such costs were charged against additional paid in capital for the funds raised during 2021.	3. Deferred Offering Costs Deferred offering costs are expenses directly related to the expected financing. These costs consisted of legal fees that the Company capitalized which will be offset against the proceeds upon completion of the financing.
Use of Estimates	4. Use of Estimates In preparing the Company’s financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE B - SIGNIFICANT ACCOUNTING POLICIES - continued	4. Use of Estimates In preparing the Company’s financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE B - SIGNIFICANT ACCOUNTING POLICIES – continued
Income Taxes	5. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740-10 Income Taxes no no	5. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740-10 Income Taxes no no
Income (Loss) Per Common Share	6. Income (Loss) Per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earnings Per Share Potentially dilutive securities not included in the computation of loss per share for the nine months ended September 30, 2021 included 3,000,000 1,820,000 199,000 3,000,000 1,800,000 62,500 4,193,000 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS September 30, 2021 and 2020 NOTE B - SIGNIFICANT ACCOUNTING POLICIES - continued	6. Income (Loss) Per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earnings Per Share Potentially dilutive securities not included in the computation of loss per share at December 31, 2020 and 2019 included 3,000,000 1,800,000 62,500 4,067,832 RETINALGENIX TECHNOLOGIES INC. NOTES TO FINANCIAL STATEMENTS December 31, 2020 and 2019 NOTE B - SIGNIFICANT ACCOUNTING POLICIES - continued
Stock-based compensation	7. Stock-based compensation The Company recognizes expense for stock-based compensation in accordance with ASC Topic 718, Stock-Based Compensation	7. Stock-based Compensation The Company recognizes expense for stock-based compensation in accordance with ASC Topic 718, Stock-Based Compensation
Research and Development costs	8. Research and Development costs Research and development costs are expensed as incurred.	8. Research and Development Costs Research and development costs are expensed as incurred.
Recent Accounting Pronouncements	9. Recent Accounting Pronouncements The following pronouncement may have an impact on the accounting policies of the Company: In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, Classification of Certain Cash Receipts and Cash Payments A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether the implementation of such proposed standards would be material to the financial statements of the Company.	9. Recent Accounting Pronouncements The following pronouncements may have an impact on the accounting policies of the Company: In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, Classification of Certain Cash Receipts and Cash Payments A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether the implementation of such proposed standards would be material to the financial statements of the Company.

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
SCHEDULE OF RELATED PARTY TRANSACTIONS	The following summarizes the transactions between the Company and Sanovas for the nine months ended September 30, 2021 and 2020: SCHEDULE OF RELATED PARTY TRANSACTIONS Nine Months Ended September 30, 2021 2020 Balance due from Sanovas – beginning of period $ (15,069 ) $ - Costs paid by Sanovas on the Company’s behalf 34,510 87,785 Costs of Sanovas allocated to the Company 750,639 1,248,154 Repayment of costs charged by Sanovas to the Company (215,489 ) (1,099,200 ) Subtotal 554,591 236,739 Retirement of due to Sanovas through the issuance of 390,358 358,126 (390,358 ) (358,126 ) Balance due to Sanovas at September 30, $ 164,233 $ (121,387 )	The following summarizes the transactions between the Company and Sanovas for the years ended December 31, 2020 and 2019: SCHEDULE OF RELATED PARTY TRANSACTIONS Year ended December 31, 2020 2019 Balance due from Sanovas – beginning of period - - Costs paid by Sanovas on the Company’s behalf $ 127,967 $ 26,837 Costs of Sanovas allocated to the Company 1,301,246 692,420 Repayment of costs charged by Sanovas to the Company (1,086,156 ) (103,200 ) Subtotal 343,057 616,057 Capital Contribution by Sanovas (see Note F) - (350,000 ) Retirement of due to Sanovas through issuance of 358,126 266,056 (358,126 ) (266,057 ) Balance due from Sanovas $ 15,069 $ 0

STOCK PLAN (Tables)

STOCK PLAN (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stock Plan
SCHEDULE OF STOCK OPTION ACTIVITY	SCHEDULE OF STOCK OPTION ACTIVITY Options Issued Weighted- Options outstanding – December 31, 2019 1,800,000 $ 1.00 Granted - - Canceled - - Exercised - - Options outstanding – December 31, 2020 1,800,000 1.00 Granted 20,000 1.00 Canceled - - Exercised - - Options outstanding – September 30, 2021 1,820,000 $ 1.00	SCHEDULE OF STOCK OPTION ACTIVITY Options Issued Weighted-Average Exercise Price Options outstanding December 31, 2018 - - Granted 4,300,000 $ 0.42 Canceled - - Exercised (2,500,000 ) $ 0.0001 Options outstanding – December 31, 2019 1,800,000 $ 1.00 Granted - - Canceled - - Exercised - - Options outstanding – December 31, 2020 1,800,000 $ 1.00
SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE	Additional information regarding the exercisable options and average remaining contractual life of the options outstanding as of September 30, 2021 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number Weighted Average Number December 31, Number September 30, $ 1.00 1,820,000 3.5 405,000 605,000	Additional information regarding the exercisable options and average remaining contractual life of the options outstanding as of December 31, 2020 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable at December 31, 2020 Number Exercisable at December 31, 2019 $ 1.00 1,800,000 4 405,000 45,000
SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS	SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.42 % Expected life in years 5.0 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00	SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.38 % Expected life in years 5.0 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Warrants
SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS	SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.42 % Expected life in years 3.5 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00	SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Risk-free interest rates 2.42 % Expected life in years 3.5 Expected volatility 73.1 % Expected dividend yield 0 % Fair value common stock $ 1.00
SCHEDULE OF WARRANTS ACTIVITY	The following table summarizes warrant activity during 2021 and 2020: SCHEDULE OF WARRANTS ACTIVITY Warrants Issued Weighted- Warrants outstanding – December 31, 2019 62,500 $ 1.00 Granted - - Canceled - - Exercised - - Warrants outstanding – December 31, 2020 62,500 $ 1.00 Granted 150,000 $ 1.10 Canceled - - Exercised (13,500 ) $ 1.00 Warrants outstanding – September 30, 2021 199,000 $ 1.07	The following table summarizes warrant activity during 2020 and 2019: SCHEDULE OF WARRANTS ACTIVITY Warrants Issued Weighted-Average Exercise Price Warrants outstanding - December 31, 2018 8,640,000 $ 0.0001 Granted 62,500 $ 1.00 Canceled - - Exercised (8,640,000 ) $ 0.0001 Warrants outstanding – December 31, 2019 62,500 $ 1.00 Granted - - Canceled - - Exercised - - Warrants outstanding – December 31, 2020 62,500 $ 1.00
SCHEDULE OF WARRANTS OUTSTANDING	Additional information regarding the warrants outstanding as of September 30, 2021 is as follows: SCHEDULE OF WARRANTS OUTSTANDING Exercise Number Weighted Average Number $ 1.00 49,000 1.7 49,000 $ 1.10 150,000 6.2 150,000	Additional information regarding the exercisable warrants and average remaining contractual life of the warrants outstanding as of December 31, 2020 is as follows: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable $ 1.00 62,500 2.5 62,500

HISTORY, BUSINESS PURPOSE, LI_2

HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)	Oct. 08, 2019	Jun. 30, 2021	Jul. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capital contribution							$ 350,000
Value of shares issuance to offset due amounts				$ 215,489	$ 1,099,200	1,086,156	103,200
Sanovas Ophthalmology LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capital contribution							350,000
Value of shares issuance to offset due amounts						358,000	266,000
Sanovas Ophthalmology LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Value of shares issuance to offset due amounts		$ 390,358	$ 358,126
Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of private offering				$ 851,000		$ 1,395,000	$ 185,000
Option Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Options to purchase shares, percentage	10.00%

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Unrecognized tax benefits	$ 0		$ 0	$ 0
Accrued penalties and interest	$ 0		$ 0	$ 0
Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per shares	3,000,000	3,000,000	3,000,000	3,000,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per shares	1,820,000	1,800,000	1,800,000	1,800,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per shares	199,000	62,500	62,500	62,500
Diopsys, Inc. [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per shares	4,193,000		4,067,832

SCHEDULE OF RELATED PARTY TRANS

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transactions [Abstract]
Balance due from Sanovas - beginning of period	$ 15,069	$ 0	$ 0	$ 0
Costs paid by Sanovas on the Company's behalf	34,510	87,785	127,967	26,837
Costs of Sanovas allocated to the Company	750,639	1,248,154	1,301,246	692,420
Repayment of costs charged by Sanovas to the Company	(215,489)	(1,099,200)	(1,086,156)	(103,200)
Subtotal	554,591	236,739	343,057	616,057
Capital Contribution by Sanovas				(350,000)
Retirement of due to Sanovas through the issuance of 390,358 and 358,126 shares of common stock to Sanovas Ophthalmology, respectively	(390,358)	(358,126)	(358,126)	(266,057)
Balance due to Sanovas - ending of period	164,233	(121,387)	15,069	0
Balance due from Sanovas - beginning of period	$ (15,069)	$ 0	$ 0	$ 0

SCHEDULE OF RELATED PARTY TRA_2

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Sanovas Ophthalmology LLC [Member]
Number of issuance of shares due to retirement	390,358	358,126	358,126	266,056

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2021	Jul. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Related party cost			$ 750,639	$ 1,248,154	$ 1,301,246	$ 692,420
Sanovas Ophthalmology LLC [Member]
Related Party Transaction [Line Items]
Related party cost			$ 360,000	$ 360,000	$ 780,000	$ 780,000
Value of shares issuance to offset due amounts	390,358	358,126				266,056

COMMON AND PREFERRED STOCK (Det

COMMON AND PREFERRED STOCK (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended			13 Months Ended
	May 31, 2015	Jan. 01, 2012	Jun. 24, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2012	Jan. 08, 2018
Class of Stock [Line Items]
Preferred stock, shares authorized				40,000,000		40,000,000	40,000,000			40,000,000
Common stock, shares authorized				80,000,000		80,000,000	80,000,000			80,000,000
Preferred stock, par value				$ 0.0001		$ 0.0001	$ 0.0001			$ 0.0001
Common stock, par value				$ 0.0001		$ 0.0001	$ 0.0001			$ 0.0001
Sale of stock, shares issued			664,973
Offering costs						$ 43,787
Preferred stock, voting right				The right to elect two directors shall terminate on the date upon which there are less than 25,000 shares of Series F preferred stock issued and outstanding.		The right to elect two directors shall terminate on the date upon which there are less than 25,000 shares of Series F preferred stock issued and outstanding.
Preferred stock, shares outstanding				3,000,000		3,000,000	3,000,000
Private Placement [Member]
Class of Stock [Line Items]
Shares issued price per share							$ 1
Sale of stock, shares issued				851,000	1,051,000	1,405,141	185,000
Offering costs						$ 10,000
Due to related parties							$ 25,000
Sanovas Ophthalmology LLC [Member]
Class of Stock [Line Items]
Number of shares issued during period								27,000,000
Original Employment Agreement [Member] | Mr. Gerrans [Member]
Class of Stock [Line Items]
Number of restricted shares issued		441,177							441,177
Percentage of shares issued		7.50%
Amended and Restated Employment Agreement [Member] | Mr. Gerrans [Member]
Class of Stock [Line Items]
Percentage of shares issued	7.50%
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized										3,000,000
Shares issued price per share				$ 0.01		$ 0.01
Preferred stock, shares outstanding				25,000		25,000
Preferred stock, dividend				$ 0		$ 0
Preferred stock, conversion price				$ 0.01		$ 0.01
Proceeds from issuance of preferred stock				$ 15,000,000		$ 15,000,000
Series F Preferred Stock [Member] | Halo Management LLC [Member]
Class of Stock [Line Items]
Number of shares issued during period								3,000,000
Series F Preferred Stock [Member] | Original Employment Agreement [Member] | Mr. Gerrans [Member]
Class of Stock [Line Items]
Number of restricted shares issued		5,000
Series F Preferred Stock [Member] | Amended and Restated Employment Agreement [Member] | Mr. Gerrans [Member]
Class of Stock [Line Items]
Number of restricted shares issued	5,000

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock Plan
Stock Options, Outstanding, Beginning Balance	1,800,000	1,800,000
Weighted Average Exercise Price, Beginning Balance	$ 1	$ 1
Stock Options, Granted	20,000		4,300,000
Weighted Average Exercise Price, Granted	$ 1		$ 0.42
Stock Options, Canceled
Weighted Average Exercise Price, Canceled
Stock Options, Exercised			(2,500,000)
Weighted Average Exercise Price, Exercised			$ 0.0001
Stock Options, Outstanding, Ending Balance	1,820,000	1,800,000	1,800,000
Weighted Average Exercise Price, Ending Balance	$ 1	$ 1	$ 1

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Stock Plan
Exercise Price	$ 1	$ 1	$ 1
Number of Options Outstanding	1,820,000	1,800,000	1,800,000
Weighted Average Remaining Contractual Life	3 years 6 months	4 years
Number of Options Exercisable	605,000	405,000	45,000

SCHEDULE OF STOCK OPTIONS FAIR

SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock Plan
Risk-free interest rates		2.42%	2.38%
Expected life in years		5 years	5 years
Expected volatility		73.10%	73.10%
Expected dividend yield	0.00%	0.00%	0.00%
Fair value common stock		$ 1	$ 1

STOCK PLAN (Details Narrative)

STOCK PLAN (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2019	Apr. 30, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares reserved for future issuance			5,680,000		5,680,000		5,700,000
Stock based compensation expense			$ 55,051	$ 55,051	$ 252,867	$ 165,153	$ 220,206	$ 27,776
Unrecognized compensation expense			$ 688,000		$ 688,000		$ 1,074,000
Weighted-average period for recognition					2 years 10 months 24 days		3 years 9 months 18 days
Fair value of share price			$ 0.61		$ 0.61		$ 0.61
Expected dividend yield					0.00%		0.00%	0.00%
2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares reserved for future issuance			10,000,000		10,000,000		10,000,000
Number of stock options to purchase common stock									0
Exercise price	$ 1	$ 0.0001	$ 1		$ 1
Aggregate fair value of stock options	$ 1,101,028	$ 250	$ 12,200		$ 12,200
Options, vesting period	5 years
2017 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options to purchase common stock	1,800,000	2,500,000			20,000

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rates		2.42%	2.38%
Expected life in years		5 years	5 years
Expected volatility		73.10%	73.10%
Expected dividend yield	0.00%	0.00%	0.00%
Fair value common stock		$ 1	$ 1
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rates	2.42%
Expected life in years	3 years 6 months
Expected volatility	73.10%
Expected dividend yield	0.00%
Fair value common stock	$ 1

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Warrants
Warrants, Outstanding, Beginning Balance	62,500	62,500	8,640,000
Weighted Average Exercise Price, Beginning Balance	$ 1	$ 1	$ 0.0001
Warrants, Granted	150,000		62,500
Weighted Average Exercise Price, Granted	$ 1.10		$ 1
Warrants, Canceled
Weighted Average Exercise Price, Canceled
Warrants, Exercised	(13,500)		(8,640,000)
Weighted Average Exercise Price, Exercised	$ 1		$ 0.0001
Warrants, Outstanding, Ending Balance	199,000	62,500	62,500
Weighted Average Exercise Price, Ending Balance	$ 1.07	$ 1	$ 1

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price		$ 1
Number Outstanding	199,000	62,500	62,500	8,640,000
Weighted Average Remaining Contractual Life		2 years 6 months
Number Exercisable		62,500
Exercise Price One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1
Number Outstanding	49,000
Weighted Average Remaining Contractual Life	1 year 8 months 12 days
Number Exercisable	49,000
Exercise Price Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.10
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	6 years 2 months 12 days
Number Exercisable	150,000

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	May 31, 2019	Mar. 31, 2019	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Net amount of shares issued				$ 13,500					$ 896
Warrant exercise price								$ 1
Warrants estimated fair value								$ 1	$ 1
Amount contributed to captial									$ 350,000
Deemed dividend
Dividend yield, percentage						0.00%		0.00%	0.00%
Stock based compensation expense			$ 55,051		$ 55,051	$ 252,867	$ 165,153	$ 220,206	$ 27,776
Unrecognized compensation expenses			$ 688,000			$ 688,000		$ 1,074,000
Warrant [Member]
Warrants estimated fair value			$ 1			$ 1
Dividend yield, percentage						0.00%
Stock based compensation expense						$ 75,500
Unrecognized compensation expenses			$ 0			$ 0
Consulting Firm [Member]
Issuance of warrants to purchase common stock			150,000			150,000
Warrant exercise price			$ 1.10			$ 1.10
Warrants estimated fair value			$ 0.61			$ 0.61
Warrants term			7 years			7 years
Sanovas Offering [Member]
Issuance of warrants to purchase common stock									62,500
Warrant exercise price									$ 1
Offering value of common stock designated									$ 5,000,000
Amount contributed to captial									$ 350,000
Warrants term									3 years
Common Stock [Member]
Net amount of shares issued				$ 1					$ 896
Number of shares issued				13,500					8,964,000
Deemed dividend
Warrant [Member]
Deemed dividend									$ 38,230
Mathematical Error [Member]
Decrease in awards of common stock	324,000
Warrants estimated fair value	$ 32
CEO and Consultant [Member]
Net amount of shares issued		$ 929
Issuance of warrants to purchase common stock		9,288,000
Warrant exercise price		$ 0.0001

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, limitation on use	the Company had net operating loss carryforwards (“NOL”) of approximately $2,058,000 for federal income tax purposes of which $1,283,000 has no expiration date, $775,000 which begins to expire in 2034, and approximately $2,058,000 for state income tax purposes which begins to expire in 2030.
Operating loss carryforwards	$ 2,058,000
Deferred tax assets, net	788,000	$ 232,000
Changes in valuation allowance	556,000	$ 232,000
No Expiration Date [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	1,283,000
Expire in 2034 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	775,000
Expire in 2030 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 2,058,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - $ / shares	Nov. 21, 2021	Nov. 19, 2021	Jun. 24, 2021	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Sale of stock, shares issued			664,973
Sale of stock price per share			$ 1
Warrant exercise price						$ 1
Consulting Firm [Member]
Subsequent Event [Line Items]
Issuance of warrants to purchase common stock					150,000
Warrant exercise price					$ 1.10
Warrants term					7 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of stock, shares issued		170,000
Sale of stock price per share		$ 1
Subsequent Event [Member] | Directors [Member] | Halo Management Group LLC [Member] | Series F Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares rescinded	3,000,000
Subsequent Event [Member] | Consulting Firm [Member]
Subsequent Event [Line Items]
Issuance of warrants to purchase common stock				150,000
Warrant exercise price				$ 1.10
Warrants term				7 years